Amphastar enters exclusive BAQSIMI distribution deal for Greater China with related party

Amphastar Pharmaceuticals, Inc.

Exclusive distributor Chengong will market BAQSIMI in Mainland China, Taiwan, Hong Kong, Macau.
Chengong must obtain regulatory approvals and conduct post-marketing clinical trials.
10-year term; minimum purchase amounts per contract year; profit sharing above floor price.
Related party: CEO Jack Zhang and Chairman Mary Luo family own majority of Chengong's parent Hanxin.
Audit Committee approved the deal; total revenue over 10 years not yet determinable.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.